Physicians' Health Study: Aspirin and Primary Prevention of Coronary Heart Disease

New England Journal of Medicine

Volumn 321, Issue 26, 1989, Pages 1825-1828

  Khaw, Kay Tee ^a   Patrono, Carlo ^b   Fitzgerald, Garret A ^c   Kaplan, Robert M ^d   Bader, Max ^e   Taylor, D W ^f   Barnett, H J M ^g   Baudoin, Claude ^h   Balkau, Beverley ^h   Eschwege, Eveline ^h   Fuster, Valentin ^j   Cohen, Marc ^j   Halperin, Jonathan ^j  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b Catholic University   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e McMaster University ^*  (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g ROBARTS RESEARCH INSTITUTE   (Canada)

^h INSERM   (France)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j MOUNT SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ADULT; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; HUMAN; MALE; NOTE; PHYSICIAN; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART DISEASE; HEART INFARCTION; LETTER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ASPIRIN; CARDIOVASCULAR DISEASES; CORONARY DISEASE; HUMAN; MALE; MIDDLE AGE; PHYSICIANS;

EID: 0024980429     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198912283212610     Document Type: Letter

References (25)

1. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129–35.
2. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313–6.
3. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982; 248: 1465–77.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
5. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396–403.
6. Peto R, Gray R. Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313–6.
7. De Caterina R, Giannessi D, Boem A, et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemost 1985; 54: 528–32.
8. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206–11.
9. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129–35.
10. Steering Committee of the Physicians' Health Study Research Group Preliminary report: findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988; 318: 262–4.
11. Peto R, Gray R, Collins R, et al. A randomised trial of the effects of prophylactic daily aspirin among male British doctors. Br Med J (in press).
12. Wolf PA, Kannel WB, Cupples LA, et al. Risk factor interaction in cardiovascular and cerebrovascular disease. In: Furlan FJ, ed. The heart and stroke: exploring mutual cerebrovascular and cardiovascular issues. London: Springer-Verlag, 1987:331–55.
13. Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978; 28: 754–62.
14. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
15. Fuster V, Cohen M, Halperin J. Aspirin in the prevention of coronary disease. N Engl J Med 1989; 321: 183–5.
16. Colwell JA. Platelets, endothelium and diabetic vascular disease. Diabete Metab 1988; 14: 512–8.
17. Baudoin C, Bousser MG, Haguenau M, Lefauconnier JM, Eschwege E. Secondary prevention of strokes: role of platelet antiaggregant drugs in diabetic and non-diabetic patients. Diabetic Med 1985; 2: 145–6.
18. Baudoin C, Passa P, Sharp P, Kohner EM, DAMAD Study Group. The effect of aspirin alone and aspirin and dipyridamole in early diabetic retinopathy: a cooperative controlled clinical trial. Diabetes 1989; 38: 491–8.
19. Kohner EM, Sleightholm MA. Does microaneurysm count reflect the severity of early diabetic retinopathy? Ophthalmology 1986; 93: 586–9.
20. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520–6.
21. Klein The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 10: 527–32.
22. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 321–31.
23. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80: 749–56.
24. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
25. DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes 1989; 38: 491–8.